Racura Oncology clears RC220 dose escalation to 100 mg/m2 in Phase 1 HARNESS-1 NSCLC trial
AZN•Racura Oncology cleared RC220 dose escalation to 100 mg/m2 in the Phase 1 HARNESS-1 trial, which combines RC220 with AstraZeneca’s osimertinib for EGFR-mutant NSCLC. The initial low-dose cohort had no dose-limiting toxicities or treatment-related safety concerns; clinical activity results were not presented.
1. Dose escalation cleared
A safety review cleared Racura Oncology to escalate RC220 dosing in the Phase 1 HARNESS-1 trial, which combines the drug with AstraZeneca’s osimertinib in EGFR-mutant NSCLC. The study will enroll its next cohort at 100 mg/m2 after the initial low-dose cohort showed no dose-limiting toxicities or treatment-related safety concerns. Clinical activity results were not presented.
